
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte has demonstrated significant revenue growth, primarily driven by a 10% year-over-year increase in demand for its leading drug Jakafi along with a successful commercial launch of Niktivmo. The company also reported strong performance from Opzelura, with revenue exceeding consensus expectations at $188 million due to heightened patient demand for atopic dermatitis and vitiligo treatments. Incyte's raised guidance for FY25 to $4.23 billion - $4.32 billion, bolstered by Jakafi and other oncology products, underscores the firm's positive momentum and continued market opportunities.
Bears say
Incyte's stock faces a negative outlook primarily due to eroding pricing power for its leading drug, Jakafi, which treats rare blood cancers and graft versus host disease, suggesting potential challenges in maintaining revenue growth. Additionally, the performance of the earlier-stage pipeline appears to be lacking, with risks associated with clinical and regulatory setbacks that could hinder product launches and market acceptance. Furthermore, concerns regarding market competition, safety signals from marketed products, and general uptake challenges underscore the volatility and uncertainty surrounding Incyte's future financial performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares